ArticleEJNMMI research2023
Prospective comparison of [
Article in EJNMMI research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Al18F-NOTA-octreotide PET Imaging of the Somatostatin Receptor in Neuroendocrine Tumors
An Exploratory Study of [18F]AlF-NOTA-octreotide PET/MRI in Carotid Artery Disease
Who cites it
15 citing papers in PubMed.
- Head-to-head comparison of [European journal of nuclear medicine and molecular imaging · 2026Article
- Article
- Controversies in NEN: An ENETS position statement on the interchangeability of somatostatin receptor PET tracers.Journal of neuroendocrinology · 2026Review
- Meningioma theranostics: a retrospective analysis of somatostatin receptor PET/CT imaging and peptide receptor radionuclide therapy.European journal of nuclear medicine and molecular imaging · 2026Article
- Uptake ofEJNMMI reports · 2026Article
- ¹⁸F-AlF-NOTA-octreotide PET/CT in high-grade G3 neuroendocrine tumors and neuroendocrine carcinomas: diagnostic performance and complementarity with ¹⁸F-FDG PET/CT.European journal of nuclear medicine and molecular imaging · 2026Article
- Superior lesion detection withQuantitative imaging in medicine and surgery · 2025Article
- Review
- Tumor-induced osteomalacia secondary to phosphaturic mesenchymal tumor: a case description and literature analysis.Quantitative imaging in medicine and surgery · 2025Article
- Targeted radionuclide therapy and diagnostic imaging of SSTR positive neuroendocrine tumors: a clinical update in the new decade.Frontiers in nuclear medicine · 2025Review
- [European journal of nuclear medicine and molecular imaging · 2024Article
- Review
- Diagnostic performance and clinical impact ofTheranostics · 2024Article
- Peptide-guided adaptor-CAR T-Cell therapy for the treatment of SSTR2-expressing neuroendocrine tumors.Oncoimmunology · 2024Article
- Fluorine 18-labeled Somatostatin Analog Improves Detection of Neuroendocrine Tumors.Radiology. Imaging cancer · 2023Article
Corrections and comments
- Commented on by
Authors and funding
19 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFluorine-18-labeled SSAs have the potential to become the next-generation tracer in SSTR-imaging in neuroendocrine tumor (NET) patients given their logistical advantages over the current gold standard gallium-68-labeled SSAs. In particular, [
methodsTen patients with a histologically confirmed neuroendocrine tumor (NET) and a standard-of-care [
resultsIn total, 195 unique lesions were detected: 167 with [
conclusionThe DR of [ CLINICALTRIALS: gov/study/NCT04552847.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.